Neos Therapeutics Inc. (NEOS) Receives Buy Rating from BMO Capital Markets
Neos Therapeutics Inc. (NASDAQ:NEOS)‘s stock had its “buy” rating restated by investment analysts at BMO Capital Markets in a report issued on Tuesday. They currently have a $15.00 target price on the stock. BMO Capital Markets’ price target would suggest a potential upside of 106.75% from the stock’s current price.
Neos Therapeutics (NASDAQ:NEOS) traded down 3.907% during mid-day trading on Tuesday, hitting $7.255. 209,760 shares of the company traded hands. Neos Therapeutics has a one year low of $6.33 and a one year high of $22.02. The company’s 50-day moving average is $7.59 and its 200-day moving average is $9.11. The stock’s market capitalization is $116.59 million.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.49. Neos Therapeutics had a negative return on equity of 80.10% and a negative net margin of 968.81%. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $1.48 million. Analysts predict that Neos Therapeutics will post ($5.38) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/neos-therapeutics-inc-neos-receives-buy-rating-from-bmo-capital-markets.html
In related news, CFO Richard I. Eisenstadt bought 3,710 shares of the company’s stock in a transaction on Thursday, August 25th. The shares were purchased at an average cost of $6.82 per share, for a total transaction of $25,302.20. Following the acquisition, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.85% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC increased its stake in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock valued at $4,611,000 after buying an additional 526,876 shares during the period. BlackRock Fund Advisors increased its stake in shares of Neos Therapeutics by 58.5% in the second quarter. BlackRock Fund Advisors now owns 566,112 shares of the company’s stock valued at $5,254,000 after buying an additional 209,054 shares during the period. Bridgeway Capital Management Inc. bought a new stake in shares of Neos Therapeutics during the second quarter valued at approximately $603,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of Neos Therapeutics by 52.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 172,536 shares of the company’s stock valued at $1,601,000 after buying an additional 59,533 shares during the period. Finally, State Street Corp increased its stake in shares of Neos Therapeutics by 61.2% in the second quarter. State Street Corp now owns 104,530 shares of the company’s stock valued at $972,000 after buying an additional 39,705 shares during the period. Hedge funds and other institutional investors own 37.73% of the company’s stock.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.